Muscle Spasticity Clinical Trial
Official title:
Electrophysiological Assessment of Cryoneurotomy in Spastic Lower Limbs.
Verified date | June 2024 |
Source | Vancouver Island Health Authority |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Spasticity is a common complication after many upper motor neurone disorders. Many surgical techniques have been introduced for patients with refractory spasticity though they are not without peri-operative risks. Cryoneurotomy is another procedure which is cheaper, faster and less invasive in comparison to other surgical interventions. While many studies support the use of cryoneurotomy for pain relief, there are not much studies on use of cryoneurotomy to manage spasticity. The purpose of this study to measure the effect of tibial nerve cryoneurotomy on electrophysiological and clinical spasticity measures in adult patients with spastic equinovarus or equinus foot, who will receive this procedure as a part of their treatment based on spasticity treatment available guidelines. The results will provide us valuable information like how long cryoneurotomy is effective, before regeneration happens.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | November 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria for patient group: 1. Patients who will have cryoneurotomy as part of their standard treatment for spastic equinovarus foot in VGH spasticity multidisciplinary clinic 2. Adults 18-70 years of age (male and female) 3. Ability to attend testing sessions, comply with testing protocols and provide written informed consent. 4. Able to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator). Inclusion Criteria for healthy participants: 1. Any healthy participants with the age between 18 to 70. Over 70 will be excluded due to the expected natural alterations in electrophysiological parameters 2. Able to attend and comply with the testing protocols 3. Able to provide informed written consent 4. Able to understand and speak English or have access to an appropriate interpreter Exclusion Criteria: 1. History of previous nerve procedures such as chemical neurolysis with alcohol, cryoneurotomy, any surgery of the tibial nerve. 2. Any other neurological pathology different from that responsible for the spasticity. |
Country | Name | City | State |
---|---|---|---|
Canada | Victoria General Hospital | Victoria | British Columbia |
Lead Sponsor | Collaborator |
---|---|
Vancouver Island Health Authority |
Canada,
Bollens B, Deltombe T, Detrembleur C, Gustin T, Stoquart G, Lejeune TM. Effects of selective tibial nerve neurotomy as a treatment for adults presenting with spastic equinovarus foot: a systematic review. J Rehabil Med. 2011 Mar;43(4):277-82. doi: 10.2340/16501977-0786. — View Citation
Deltombe T, Bleyenheuft C, Gustin T. Comparison between tibial nerve block with anaesthetics and neurotomy in hemiplegic adults with spastic equinovarus foot. Ann Phys Rehabil Med. 2015 Apr;58(2):54-9. doi: 10.1016/j.rehab.2014.12.003. Epub 2015 Jan 9. — View Citation
Friedman T, Richman D, Adler R. Sonographically guided cryoneurolysis: preliminary experience and clinical outcomes. J Ultrasound Med. 2012 Dec;31(12):2025-34. doi: 10.7863/jum.2012.31.12.2025. — View Citation
Ilfeld BM, Gabriel RA, Trescot AM. Ultrasound-guided percutaneous cryoneurolysis for treatment of acute pain: could cryoanalgesia replace continuous peripheral nerve blocks? Br J Anaesth. 2017 Oct 1;119(4):703-706. doi: 10.1093/bja/aex142. No abstract available. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Any changes in H max to M max amplitude ratio (H/ M ratio) | The ratio of maximum H reflex amplitude to maximum M wave amplitude as another electrophysiological analog for spasticity will be measured by a commercially available clinical electrodiagnosis machine before the procedure and at 1, 3 and 12 months after it. The results will be presented as a ratio and percentage. | up to 12 months | |
Primary | Changes in maximum H reflex amplitude | The maximum H reflex amplitude as an analog of spasticity as it measure excitability of the monosynaptic reflex arc will be assessed by a commercially available clinical electrodiagnosis machine. The assessment will be done before the procedure and at 1, 3 and 12 months after it and at both sides. The measurement unit will be millivolt (mV). | up to 12 months after procedure | |
Secondary | Degree of changes in ankle dorsi-flexion spasticity as measured by Modified Ashworth Scale (MAS) | MAS has 6 scales from 0 to 4 (0,1,1+,2,3,4) which 0 means no spasticity and 4 means the maximum spasticity and the affected limb is rigid in its position.The assessment will be done by a trained examiner which is not enrolled in providing medical care and will be done before the procedure and at 1, 3 and 12 months after the procedure. | up to 12 months after procedure | |
Secondary | Degree of changes in ankle dorsiflexion range of motion | The active and maximum passive dorsiflexion range of motion will be measured by a goniometer and will be presented in degree. The test will be done before and at 1, 3 and 12 months after the procedure by a trained examiner who is not enrolled in providing medical care. | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT02907775 -
Multi-channel Stimulation for Post Stroke Spasticity (MUSTS)
|
N/A | |
Recruiting |
NCT04530955 -
Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)
|
N/A | |
Active, not recruiting |
NCT03521076 -
Randomized Controlled Trial of Virtual Reality
|
N/A | |
Completed |
NCT03080454 -
The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
|
Phase 1/Phase 2 | |
Completed |
NCT02546999 -
Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?
|
Phase 4 | |
Active, not recruiting |
NCT01041157 -
Botulinum Toxin Injection Efficiency
|
Phase 1 | |
Completed |
NCT00535938 -
MDs on Botox Utility (MOBILITY)
|
N/A | |
Terminated |
NCT00531466 -
Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury
|
Phase 2 | |
Terminated |
NCT00532532 -
Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05546190 -
A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)
|
||
Recruiting |
NCT06117020 -
Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
|
Phase 1 | |
Completed |
NCT01603628 -
BOTOX® Treatment in Pediatric Lower Limb Spasticity
|
Phase 3 | |
Completed |
NCT05510726 -
Quantitative Evaluation of Muscle Stiffness in Neurological Patients With Muscle Overactivity
|
||
Not yet recruiting |
NCT04378946 -
Error Augmentation Motor Learning Training Approach in Stroke Patients
|
N/A | |
Completed |
NCT01603615 -
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
|
Phase 3 | |
Completed |
NCT01251380 -
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
|
Phase 3 | |
Completed |
NCT00549783 -
BOTOX® Economic Spasticity Trial (BEST)
|
Phase 4 | |
Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
Completed |
NCT00076687 -
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
|
Phase 2 |